BBO-10203

Phase 1Small molecule

TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

BBO-10203 is one of 45 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Solid Tumor, AdultRecruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Solid Tumor, AdultPhase 1

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Ofev

Boehringer Ingelheim

Preclinical

7 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vidaza

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Solid Tumor, Adult

NCT06625775

Q3 2031

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT06343402

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06343402·350 enrolled

Solid Tumor, Adult1 trial

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06625775·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BBO-10203. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BBO-10203 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BBO-10203. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

BBO-10203

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Solid Tumor, Adult1 trial

References

Drug Info

Quick Facts

Related News